Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhujun Cao

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|December 28, 2022
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19Zhujun Cao, Weiyi Gao, Hong Bao, et al.
BMJ (Clinical Research Ed.)|May 16, 2020
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialWei Tang, Zhujun Cao, Mingfeng Han, et al.
Medcomm|November 4, 2024
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort studyShanghao Liu, Jia Li, Yujun Wong, et al.
The American Journal of Gastroenterology|August 16, 2022
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort StudyChuan Liu, Zhujun Cao, Huadong Yan, et al.
The American Journal of Gastroenterology|July 19, 2023
Correction to: A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort StudyChuan Liu, Zhujun Cao, Huadong Yan, et al.
JAMA Network Open|March 13, 2024
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical TrialZhitao Yang, Yu Xu, Ruizhi Zheng, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
BMJ Open|July 11, 2024
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in ChinaChuan Liu, Liting Zhang, Shuairan Zhang, et al.
Gastroenterology|July 25, 2025
Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External ValidationScott Silvey, Patrick S Kamath, Jacob George, et al.
Gut|June 5, 2026
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspectiveFlorence Wong, Danielle Adebayo, Jacob George, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|December 28, 2022
VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19Zhujun Cao, Weiyi Gao, Hong Bao, et al.
BMJ (Clinical Research Ed.)|May 16, 2020
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialWei Tang, Zhujun Cao, Mingfeng Han, et al.
Medcomm|November 4, 2024
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort studyShanghao Liu, Jia Li, Yujun Wong, et al.
The American Journal of Gastroenterology|August 16, 2022
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort StudyChuan Liu, Zhujun Cao, Huadong Yan, et al.
The American Journal of Gastroenterology|July 19, 2023
Correction to: A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort StudyChuan Liu, Zhujun Cao, Huadong Yan, et al.
JAMA Network Open|March 13, 2024
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical TrialZhitao Yang, Yu Xu, Ruizhi Zheng, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
BMJ Open|July 11, 2024
Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in ChinaChuan Liu, Liting Zhang, Shuairan Zhang, et al.
Gastroenterology|July 25, 2025
Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External ValidationScott Silvey, Patrick S Kamath, Jacob George, et al.
Gut|June 5, 2026
Chronic kidney disease in cirrhosis: a study of inpatients from a global perspectiveFlorence Wong, Danielle Adebayo, Jacob George, et al.
Pageof 7